220127-57-1 Imatinib mesylate 98%

Fresenius Kabi Oncology Limited is a public company primarily operating in the field of Research & Development and manufacturing of world-class oncology drugs. The company strives to provide state-of-the-art third generation chemotherapeutic drugs right from development to manufacturing & marketing across the globe. It is fast emerging as a leading player in oncology generics on the strength of its comprehensive product portfolio of injectables, oral cytotoxics, cytostatics, intermediates and Active Pharmaceutical Ingredients (APIs).Fresenius Kabi Oncology Limited develops, manufactures and markets anti-cancer products for critically and chronically ill patients. As a part of the globally reputed Fresenius Healthcare Group, it plays a pivotal role in patient care, both within and outside hospitals, to efficaciously carry forward its mission of “caring for life”.

The Company has been able to leverage the global outreach in benchmarking oncology excellence with latest world class production, avant-garde manufacturing and Research & Development facilities.

The Company’s corporate logo is much more than just a symbol and represents its finest qualities-compassion, knowledge, insight and integrity. The logo implies human beings standing one behind the other (head and shoulders), visualizing the team spirit and the mission of Fresenius Kabi.